A common cancer drug blocks the relief from morphine and makes patients become immune to the painkiller faster.
April 20, 2026
Original Paper
Bevacizumab Impairs Morphine Analgesia through Tuberous Sclerosis Complex 1–Mechanistic Target of Rapamycin-Autophagy Dysregulation
SSRN · 6586867
The Takeaway
Bevacizumab is widely used to starve tumors of their blood supply, but it also disrupts a critical recycling process in the brain called autophagy. This disruption occurs specifically in the medial prefrontal cortex, which is a key area for processing pain and opioids. When this signaling pathway is broken, morphine loses its ability to dull pain effectively. Patients on this treatment often find their pain getting worse even as their opioid doses increase. Understanding this interaction explains why standard pain management often fails in certain cancer patients. Doctors may need to choose different pain relief strategies for anyone receiving these specific types of chemotherapy.
From the abstract
Background: Bevacizumab is a widely used anti-VEGF-A therapy in oncology and ophthalmology, valued for its potent anti-angiogenic effects across cancer and ocular diseases. Beyond angiogenesis, growing evidence suggests that VEGF-A also contributes to neuronal homeostasis, including autophagy regulation, synaptic plasticity, and nociceptive processing. These nonvascular actions raise the possibility that bevacizumab may influence central mechanisms of pain control, particularly in patients requi